Welcome to Equinox Pharma
Equinox Pharma is a computationally-driven drug discovery company which, in partnership with pharma companies, biotechs and medicinal chemistry-based contract research organizations, will use its capability in machine learning and chemoinformatics (together given the descriptor “INDDExTM”) to undertake a range of drug discovery collaborations. These collaborations will be based upon IP generated through Equinox programmes focused on high value validated drug targets, on the partner’s proprietary data or on data ‘mined’ specifically to address a target of interest to both parties.
Computationally-driven means that we put in silico techniques at the centre of our drug discovery activities rather than use them simply as support to high throughput screening. This allows us to capture the benefits of computational techniques such as speed and efficiency and critically enables us to discover new chemotypes. We are a semi-virtual company using our in silico models to direct the work of external medicinal chemistry and pharmacology providers.
Our internal focus is on G-protein coupled receptor (GPCR) targets with application to metabolic and CNS diseases but as our approach is applicable to other groups of drug targets with relevance to many disease areas we anticipate partnered programmes involving a wide range of drug targets.
Equinox Pharma was set up to commercialise the world leading research of three senior academics from Imperial College London. Professors Paul Freemont, Stephen Muggleton and Mike Sternberg have collaborated over many years developing expertise in the applications of machine learning, chemo- and bio-informatics and protein crystallography to drug discovery.
